| Year |
Citation |
Score |
| 2022 |
Branigan GL, Torrandell-Haro G, Soto M, Gelmann EP, Vitali F, Rodgers KE, Brinton RD. Androgen-targeting therapeutics mitigate the adverse effect of GnRH agonist on the risk of neurodegenerative disease in men treated for prostate cancer. Cancer Medicine. PMID 35293700 DOI: 10.1002/cam4.4650 |
0.491 |
|
| 2021 |
Gelmann EP. The expanding role of hormones in cancer. Endocrine Oncology (Bristol, England). 1: E1-E2. PMID 37435183 DOI: 10.1530/EO-21-0001 |
0.317 |
|
| 2020 |
Bowen C, Shibata M, Zhang H, Bergren SK, Shen MM, Gelmann EP. CRISPR/Cas9-Mediated Point Mutation in Nkx3.1 Prolongs Protein Half-Life and Reverses Effects Nkx3.1 Allelic Loss. Cancer Research. PMID 32943441 DOI: 10.1158/0008-5472.CAN-20-1742 |
0.466 |
|
| 2019 |
Bowen C, Ostrowski MC, Leone G, Gelmann EP. Loss of PTEN Accelerates NKX3.1 Degradation to Promote Prostate Cancer Progression. Cancer Research. PMID 31213464 DOI: 10.1158/0008-5472.Can-18-4110 |
0.593 |
|
| 2019 |
Molina A, Christos P, Hackett A, Nordquist L, Gelmann E, Stein M, Sternberg C, Beltran H, Gracey L, Galletti G, Giannakakou P, Nanus DM, Tagawa ST. Abstract CT097: Phase I trial of apalutamide plus abiraterone acetate, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Ct097 |
0.393 |
|
| 2018 |
Leighton X, Bera A, Eidelman O, Bubendorf L, Zellweger T, Banerjee J, Gelmann EP, Pollard HB, Srivastava M. Tissue microarray analysis delineate potential prognostic role of Annexin A7 in prostate cancer progression. Plos One. 13: e0205837. PMID 30321230 DOI: 10.1371/Journal.Pone.0205837 |
0.556 |
|
| 2018 |
Andrews C, Fortier B, Hayward A, Lederman R, Petersen L, McBride J, Petersen DC, Ajayi O, Kachambwa P, Seutloali M, Shoko A, Mokhosi M, Hiller R, Adams M, Ongaco C, ... ... Gelmann E, et al. Development, Evaluation, and Implementation of a Pan-African Cancer Research Network: Men of African Descent and Carcinoma of the Prostate. Journal of Global Oncology. 1-14. PMID 30260755 DOI: 10.1200/Jgo.18.00063 |
0.543 |
|
| 2016 |
Neugut AI, Gelmann EP. Treatment of the Prostate in the Presence of Metastases: Lessons from Other Solid Tumors. European Urology. 69: 795-6. PMID 26099904 DOI: 10.1016/J.Eururo.2015.06.004 |
0.344 |
|
| 2015 |
Zhang H, Zheng T, Chua CW, Shen M, Gelmann EP. Nkx3.1 controls the DNA repair response in the mouse prostate. The Prostate. PMID 26660523 DOI: 10.1002/Pros.23131 |
0.484 |
|
| 2015 |
Bowen C, Zheng T, Gelmann EP. NKX3.1 Suppresses TMPRSS2-ERG Gene Rearrangement and Mediates Repair of Androgen Receptor-Induced DNA Damage. Cancer Research. 75: 2686-98. PMID 25977336 DOI: 10.1158/0008-5472.Can-14-3387 |
0.487 |
|
| 2015 |
Song LN, Silva J, Koller A, Rosenthal A, Chen EI, Gelmann EP. The Tumor Suppressor NKX3.1 Is Targeted for Degradation by DYRK1B Kinase. Molecular Cancer Research : McR. 13: 913-22. PMID 25777618 DOI: 10.1158/1541-7786.Mcr-14-0680 |
0.46 |
|
| 2013 |
Muhlbradt E, Ma J, Severi G, Ortner E, Hayes V, Hoang HN, Stampfer M, Giles G, Pollak M, Gelmann EP. Variant NKX3.1 and Serum IGF-1: Investigation of Interaction in Prostate Cancer. Genes & Cancer. 4: 535-45. PMID 24386513 DOI: 10.1177/1947601913506009 |
0.672 |
|
| 2013 |
Bowen C, Ju JH, Lee JH, Paull TT, Gelmann EP. Functional activation of ATM by the prostate cancer suppressor NKX3.1. Cell Reports. 4: 516-29. PMID 23890999 DOI: 10.1016/J.Celrep.2013.06.039 |
0.423 |
|
| 2013 |
Song LN, Bowen C, Gelmann EP. Structural and functional interactions of the prostate cancer suppressor protein NKX3.1 with topoisomerase I. The Biochemical Journal. 453: 125-36. PMID 23557481 DOI: 10.1042/Bj20130012 |
0.366 |
|
| 2013 |
Lim E, Gelmann EP. Renal Cell Cancer Treated with a Single-Edged Sword Cell Reports. 3: 275-276. PMID 23438368 DOI: 10.1016/J.Celrep.2013.02.001 |
0.356 |
|
| 2012 |
Ruiz C, Oeggerli M, Germann M, Gluderer S, Stocker H, Andreozzi M, Thalmann GN, Cecchini MG, Zellweger T, Stürm S, Koivisto PA, Helin HJ, Gelmann EP, Glass AG, Gasser TC, et al. High NRBP1 expression in prostate cancer is linked with poor clinical outcomes and increased cancer cell growth. The Prostate. 72: 1678-87. PMID 22473923 DOI: 10.1002/Pros.22521 |
0.631 |
|
| 2011 |
Abate-Shen C, Meneses AA, Kinkade CW, Mitrofanova A, Lefebvre C, Chua CW, Castillo-Martin M, Gelmann E, Shen MM, Califano A. Abstract SY22-01: Interrogating gene expression programs from preclinical analyses of genetically engineered mouse models Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Sy22-01 |
0.573 |
|
| 2010 |
Bowen C, Gelmann EP. NKX3.1 activates cellular response to DNA damage. Cancer Research. 70: 3089-97. PMID 20395202 DOI: 10.1158/0008-5472.CAN-09-3138 |
0.339 |
|
| 2009 |
Ju JH, Maeng JS, Lee DY, Piszczek G, Gelmann EP, Gruschus JM. Interactions of the acidic domain and SRF interacting motifs with the NKX3.1 homeodomain. Biochemistry. 48: 10601-7. PMID 19780584 DOI: 10.1021/Bi9013374 |
0.312 |
|
| 2009 |
Croswell JM, Kramer BS, Kreimer AR, Prorok PC, Xu JL, Baker SG, Fagerstrom R, Riley TL, Clapp JD, Berg CD, Gohagan JK, Andriole GL, Chia D, Church TR, Crawford ED, ... ... Gelmann EP, et al. Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Annals of Family Medicine. 7: 212-22. PMID 19433838 DOI: 10.1370/Afm.942 |
0.324 |
|
| 2009 |
Gelmann EP, Henshall SM. Clinically relevant prognostic markers for prostate cancer: the search goes on. Annals of Internal Medicine. 150: 647-9. PMID 19414846 |
0.485 |
|
| 2009 |
Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, et al. Mortality results from a randomized prostate-cancer screening trial. The New England Journal of Medicine. 360: 1310-9. PMID 19297565 DOI: 10.1056/Nejmoa0810696 |
0.58 |
|
| 2009 |
Muhlbradt E, Asatiani E, Ortner E, Wang A, Gelmann EP. NKX3.1 activates expression of insulin-like growth factor binding protein-3 to mediate insulin-like growth factor-I signaling and cell proliferation. Cancer Research. 69: 2615-22. PMID 19258508 DOI: 10.1158/0008-5472.Can-08-3022 |
0.656 |
|
| 2008 |
Grubb RL, Pinsky PF, Greenlee RT, Izmirlian G, Miller AB, Hickey TP, Riley TL, Mabie JE, Levin DL, Chia D, Kramer BS, Reding DJ, Church TR, Yokochi LA, Kvale PA, ... ... Gelmann EP, et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. Bju International. 102: 1524-30. PMID 19035857 DOI: 10.1111/J.1464-410X.2008.08214.X |
0.564 |
|
| 2008 |
Markowski MC, Bowen C, Gelmann EP. Inflammatory cytokines induce phosphorylation and ubiquitination of prostate suppressor protein NKX3.1. Cancer Research. 68: 6896-901. PMID 18757402 DOI: 10.1158/0008-5472.Can-08-0578 |
0.716 |
|
| 2008 |
Abate-Shen C, Shen MM, Gelmann E. Integrating differentiation and cancer: the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. Differentiation; Research in Biological Diversity. 76: 717-27. PMID 18557759 DOI: 10.1111/J.1432-0436.2008.00292.X |
0.542 |
|
| 2008 |
Taplin ME, Manola J, Oh WK, Kantoff PW, Bubley GJ, Smith M, Barb D, Mantzoros C, Gelmann EP, Balk SP. A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones. Bju International. 101: 1084-9. PMID 18399827 DOI: 10.1111/J.1464-410X.2008.07509.X |
0.548 |
|
| 2008 |
Gelmann EP. Complexities of prostate-cancer risk. The New England Journal of Medicine. 358: 961-3. PMID 18199856 DOI: 10.1056/NEJMe0708703 |
0.489 |
|
| 2008 |
Tan SH, Dagvadorj A, Shen F, Gu L, Liao Z, Abdulghani J, Zhang Y, Gelmann EP, Zellweger T, Culig Z, Visakorpi T, Bubendorf L, Kirken RA, Karras J, Nevalainen MT. Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells. Cancer Research. 68: 236-48. PMID 18172316 DOI: 10.1158/0008-5472.Can-07-2972 |
0.584 |
|
| 2008 |
Liao Z, Tan S, Dagvadorj A, Shen F, Gu L, Abdulghani J, Zhang Y, Gelmann EP, Zellweger T, Culig Z, Visakorpi T, Bubendorf L, Kirken RA, Karras J, Nevalainen MT. TRANSCRIPTION FACTOR STAT5 SYNERGIZES WITH ANDROGEN RECEPTOR IN PROSTATE CANCER CELLS Journal of Urology. 179: 186-186. DOI: 10.1016/S0022-5347(08)60540-6 |
0.508 |
|
| 2007 |
Peters U, Leitzmann MF, Chatterjee N, Wang Y, Albanes D, Gelmann EP, Friesen MD, Riboli E, Hayes RB. Serum lycopene, other carotenoids, and prostate cancer risk: a nested case-control study in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 16: 962-8. PMID 17507623 DOI: 10.1158/1055-9965.Epi-06-0861 |
0.59 |
|
| 2007 |
Schumacher FR, Feigelson HS, Cox DG, Haiman CA, Albanes D, Buring J, Calle EE, Chanock SJ, Colditz GA, Diver WR, Dunning AM, Freedman ML, Gaziano JM, Giovannucci E, Hankinson SE, ... ... Gelmann E, et al. A common 8q24 variant in prostate and breast cancer from a large nested case-control study. Cancer Research. 67: 2951-6. PMID 17409400 DOI: 10.1158/0008-5472.Can-06-3591 |
0.55 |
|
| 2007 |
Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, Minichiello MJ, Fearnhead P, Yu K, Chatterjee N, Wang Z, Welch R, Staats BJ, Calle EE, Feigelson HS, ... ... Gelmann EP, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nature Genetics. 39: 645-9. PMID 17401363 DOI: 10.1038/Ng2022 |
0.502 |
|
| 2007 |
Pinsky PF, Miller A, Kramer BS, Church T, Reding D, Prorok P, Gelmann E, Schoen RE, Buys S, Hayes RB, Berg CD. Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial American Journal of Epidemiology. 165: 874-881. PMID 17244633 DOI: 10.1093/Aje/Kwk075 |
0.4 |
|
| 2007 |
Bowen C, Stuart A, Ju JH, Tuan J, Blonder J, Conrads TP, Veenstra TD, Gelmann EP. NKX3.1 homeodomain protein binds to topoisomerase I and enhances its activity. Cancer Research. 67: 455-64. PMID 17234752 DOI: 10.1158/0008-5472.CAN-06-1591 |
0.384 |
|
| 2007 |
Pinsky PF, Crawford ED, Kramer BS, Andriole GL, Gelmann EP, Grubb R, Greenlee R, Gohagan JK. Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial. Bju International. 99: 775-9. PMID 17223921 DOI: 10.1111/J.1464-410X.2007.06708.X |
0.581 |
|
| 2006 |
True L, Coleman I, Hawley S, Huang CY, Gifford D, Coleman R, Beer TM, Gelmann E, Datta M, Mostaghel E, Knudsen B, Lange P, Vessella R, Lin D, Hood L, et al. A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America. 103: 10991-6. PMID 16829574 DOI: 10.1073/Pnas.0603678103 |
0.598 |
|
| 2006 |
Ju JH, Maeng JS, Zemedkun M, Ahronovitz N, Mack JW, Ferretti JA, Gelmann EP, Gruschus JM. Physical and functional interactions between the prostate suppressor homeoprotein NKX3.1 and serum response factor. Journal of Molecular Biology. 360: 989-99. PMID 16814806 DOI: 10.1016/J.Jmb.2006.05.064 |
0.373 |
|
| 2006 |
Shand RL, Gelmann EP. Molecular biology of prostate-cancer pathogenesis. Current Opinion in Urology. 16: 123-31. PMID 16679847 DOI: 10.1097/01.Mou.0000193384.39351.64 |
0.569 |
|
| 2006 |
Crawford ED, Pinsky PF, Chia D, Kramer BS, Fagerstrom RM, Andriole G, Reding D, Gelmann EP, Levin DL, Gohagan JK. Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial. The Journal of Urology. 175: 1286-90; discussion . PMID 16515981 DOI: 10.1016/S0022-5347(05)00706-8 |
0.547 |
|
| 2006 |
Rodriguez Ortner E, Hayes RB, Weissfeld J, Gelmann EP. Effect of homeodomain protein NKX3.1 R52C polymorphism on prostate gland size. Urology. 67: 311-5. PMID 16442598 DOI: 10.1016/J.Urology.2005.08.021 |
0.515 |
|
| 2006 |
Zheng SL, Ju JH, Chang BL, Ortner E, Sun J, Isaacs SD, Sun J, Wiley KE, Liu W, Zemedkun M, Walsh PC, Ferretti J, Gruschus J, Isaacs WB, Gelmann EP, et al. Germ-line mutation of NKX3.1 cosegregates with hereditary prostate cancer and alters the homeodomain structure and function. Cancer Research. 66: 69-77. PMID 16397218 DOI: 10.1158/0008-5472.Can-05-1550 |
0.611 |
|
| 2006 |
Hayes JH, Oh WK, Kantoff PW, Manola JB, Smith MR, Gelmann EP, Bubley G, Balk SP, Taplin M. Mifepristone (RU-486) in androgen independent prostate cancer Journal of Clinical Oncology. 24: 14508-14508. DOI: 10.1200/Jco.2006.24.18_Suppl.14508 |
0.481 |
|
| 2005 |
Li H, Zhang Y, Glass A, Zellweger T, Gehan E, Bubendorf L, Gelmann EP, Nevalainen MT. Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 5863-8. PMID 16115927 DOI: 10.1158/1078-0432.Ccr-05-0562 |
0.581 |
|
| 2005 |
Mani A, Gelmann EP. The ubiquitin-proteasome pathway and its role in cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 4776-89. PMID 16034054 DOI: 10.1200/Jco.2005.05.081 |
0.324 |
|
| 2005 |
Andriole GL, Levin DL, Crawford ED, Gelmann EP, Pinsky PF, Chia D, Kramer BS, Reding D, Church TR, Grubb RL, Izmirlian G, Ragard LR, Clapp JD, Prorok PC, Gohagan JK. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: Findings from the initial screening round of a randomized trial Journal of the National Cancer Institute. 97: 433-438. PMID 15770007 DOI: 10.1093/Jnci/Dji065 |
0.528 |
|
| 2005 |
Asatiani E, Huang WX, Wang A, Rodriguez Ortner E, Cavalli LR, Haddad BR, Gelmann EP. Deletion, methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancer. Cancer Research. 65: 1164-73. PMID 15734999 DOI: 10.1158/0008-5472.Can-04-2688 |
0.528 |
|
| 2005 |
Gohagan JK, Marcus PM, Fagerstrom RM, Pinsky PF, Kramer BS, Prorok PC, Ascher S, Bailey W, Brewer B, Church T, Engelhard D, Ford M, Fouad M, Freedman M, Gelmann E, et al. Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer. Lung Cancer (Amsterdam, Netherlands). 47: 9-15. PMID 15603850 DOI: 10.1016/J.Lungcan.2004.06.007 |
0.323 |
|
| 2004 |
Gelmann EP, Semmes OJ. Expression of genes and proteins specific for prostate cancer. The Journal of Urology. 172: S23-6; discussion S2. PMID 15535438 |
0.519 |
|
| 2004 |
Carroll PR, Chan JM, D'Amico AV, Gelmann EP, Iversen P, Klotz L, Nelson JB, Nelson PS, Nelson WG, Oh WK, Rosen N, Rubin MA, Sandler H, Sellers WR, Smith MR, et al. Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment. The Journal of Urology. 172: S3-5. PMID 15535434 DOI: 10.1097/01.ju.0000142276.19511.ac |
0.469 |
|
| 2004 |
Amin A, Halabi S, Gelmann EP, Stadler W, Vogelzang N, Small E. 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901. Urologic Oncology. 22: 398-403. PMID 15464920 DOI: 10.1016/J.Urolonc.2004.05.002 |
0.526 |
|
| 2004 |
Taylor KL, Shelby R, Gelmann E, McGuire C. Quality of life and trial adherence among participants in the prostate, lung, colorectal, and ovarian cancer screening trial. Journal of the National Cancer Institute. 96: 1083-94. PMID 15265970 DOI: 10.1093/Jnci/Djh194 |
0.342 |
|
| 2004 |
Song LN, Coghlan M, Gelmann EP. Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor. Molecular Endocrinology (Baltimore, Md.). 18: 70-85. PMID 14593076 DOI: 10.1210/Me.2003-0189 |
0.439 |
|
| 2004 |
Andriole GL, Pinsky PF, Levin DL, Gelmann EP, Crawford ED, Reding DJ, Prorok PC, Gohagan JF. 1791: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: Biopsy Rates and Cancer Characteristics of Initial (To) Screen (II) Journal of Urology. 171: 473-473. DOI: 10.1016/s0022-5347(18)38983-3 |
0.378 |
|
| 2003 |
Gelmann EP. Searching for the gatekeeper oncogene of prostate cancer. Critical Reviews in Oncology/Hematology. 46: S11-20. PMID 12850523 DOI: 10.1016/S1040-8428(03)00060-X |
0.618 |
|
| 2003 |
Gelmann EP, Bowen C, Bubendorf L. Expression of NKX3.1 in normal and malignant tissues. The Prostate. 55: 111-7. PMID 12661036 DOI: 10.1002/Pros.10210 |
0.544 |
|
| 2003 |
Zellweger T, Ninck C, Mirlacher M, Annefeld M, Glass AG, Gasser TC, Mihatsch MJ, Gelmann EP, Bubendorf L. Tissue microarray analysis reveals prognostic significance of syndecan-I expression in prostate cancer Prostate. 55: 20-29. PMID 12640657 DOI: 10.1002/Pros.10209 |
0.516 |
|
| 2002 |
Gelmann EP. Molecular biology of the androgen receptor. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 3001-15. PMID 12089231 DOI: 10.1200/Jco.2002.10.018 |
0.549 |
|
| 2002 |
Gelmann EP, Steadman DJ, Ma J, Ahronovitz N, Voeller HJ, Swope S, Abbaszadegan M, Brown KM, Strand K, Hayes RB, Stampfer MJ. Occurrence of NKX3.1 C154T polymorphism in men with and without prostate cancer and studies of its effect on protein function. Cancer Research. 62: 2654-9. PMID 11980664 |
0.513 |
|
| 2002 |
Martin MB, Voeller HJ, Gelmann EP, Lu J, Stoica EG, Hebert EJ, Reiter R, Singh B, Danielsen M, Pentecost E, Stoica A. Role of cadmium in the regulation of AR gene expression and activity. Endocrinology. 143: 263-75. PMID 11751618 DOI: 10.1210/Endo.143.1.8581 |
0.478 |
|
| 2001 |
Gelmann EP, Chia D, Pinsky PF, Andriole GL, Crawford ED, Reding D, Hayes RB, Kramer BS, Woodrum DL, Gohagan JK, Levin DL. Relationship of demographic and clinical factors to free and total prostate-specific antigen. Urology. 58: 561-6. PMID 11597539 DOI: 10.1016/S0090-4295(01)01305-X |
0.497 |
|
| 2000 |
Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, Fogel R, Gelmann EP, Gilbert F, Hasson MA, Hayes RB, Johnson CC, Mandel JS, Oberman A, O'Brien B, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Controlled Clinical Trials. 21: 273S-309S. PMID 11189684 DOI: 10.1016/S0197-2456(00)00098-2 |
0.468 |
|
| 2000 |
Steadman DJ, Giuffrida D, Gelmann EP. DNA-binding sequence of the human prostate-specific homeodomain protein NKX3.1. Nucleic Acids Research. 28: 2389-95. PMID 10871372 DOI: 10.1093/Nar/28.12.2389 |
0.372 |
|
| 1999 |
Bowen C, Voeller HJ, Kikly K, Gelmann EP. Synthesis of procaspases-3 and -7 during apoptosis in prostate cancer cells. Cell Death and Differentiation. 6: 394-401. PMID 10381629 DOI: 10.1038/sj.cdd.4400502 |
0.311 |
|
| 1998 |
Stearns V, Gelmann EP. Does tamoxifen cause cancer in humans? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 779-92. PMID 9469370 DOI: 10.1200/Jco.1998.16.2.779 |
0.336 |
|
| 1997 |
He WW, Sciavolino PJ, Wing J, Augustus M, Hudson P, Meissner PS, Curtis RT, Shell BK, Bostwick DG, Tindall DJ, Gelmann EP, Abate-Shen C, Carter KC. A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer Genomics. 43: 69-77. PMID 9226374 DOI: 10.1006/geno.1997.4715 |
0.514 |
|
| 1997 |
Cardillo M, Berchem G, Tarkington MA, Krajewski S, Krajewski M, Reed JC, Tehan T, Ortega L, Lage J, Gelmann EP. Resistance to apoptosis and up regulation of Bcl-2 in benign prostatic hyperplasia after androgen deprivation. The Journal of Urology. 158: 212-6. PMID 9186362 DOI: 10.1097/00005392-199707000-00073 |
0.564 |
|
| 1997 |
Gumerlock PH, Chi SG, Shi XB, Voeller HJ, Jacobson JW, Gelmann EP, deVere White RW. p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network. Journal of the National Cancer Institute. 89: 66-71. PMID 8978408 DOI: 10.1093/Jnci/89.1.66 |
0.527 |
|
| 1997 |
Gelmann EP. Androgen receptor mutations in prostate cancer. Cancer Treatment and Research. 87: 285-302. PMID 8886458 DOI: 10.1007/978-1-4613-1267-3_12 |
0.469 |
|
| 1994 |
Voeller HJ, Sugars LY, Pretlow T, Gelmann EP. p53 oncogene mutations in human prostate cancer specimens. The Journal of Urology. 151: 492-5. PMID 7904314 DOI: 10.1016/S0022-5347(17)35000-0 |
0.389 |
|
| 1993 |
Carroll AG, Voeller HJ, Sugars L, Gelmann EP. p53 oncogene mutations in three human prostate cancer cell lines. The Prostate. 23: 123-34. PMID 8104329 DOI: 10.1002/pros.2990230206 |
0.354 |
|
| 1991 |
Voeller HJ, Wilding G, Gelmann EP. v-rasH expression confers hormone-independent in vitro growth to LNCaP prostate carcinoma cells. Molecular Endocrinology (Baltimore, Md.). 5: 209-16. PMID 2038342 DOI: 10.1210/Mend-5-2-209 |
0.505 |
|
| 1990 |
Wilding G, Gelmann EP, Freter CE. Phosphoinositide metabolism in human prostate cancer cells in vitro. The Prostate. 16: 15-27. PMID 2154736 DOI: 10.1002/Pros.2990160103 |
0.377 |
|
| 1989 |
Wilding G, Valverius E, Knabbe C, Gelmann EP. Role of transforming growth factor-alpha in human prostate cancer cell growth. The Prostate. 15: 1-12. PMID 2798227 DOI: 10.1002/Pros.2990150102 |
0.34 |
|
| 1989 |
Wilding G, Chen M, Gelmann EP. Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. The Prostate. 14: 103-15. PMID 2710689 DOI: 10.1002/Pros.2990140204 |
0.44 |
|
| Show low-probability matches. |